Acute myeloid leukemia
JE Rubnitz, B Gibson, FO Smith - Pediatric clinics of North America, 2008 - Elsevier
Acute myeloid leukemia (AML) is a heterogeneous group of leukemias that result from clonal
transformation of hematopoietic precursors through the acquisition of chromosomal …
transformation of hematopoietic precursors through the acquisition of chromosomal …
Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome
Children with Down syndrome (DS) show a spectrum of clinical anomalies, including
cognitive impairment, cardiac malformations, and craniofacial dysmorphy. Moreover …
cognitive impairment, cardiac malformations, and craniofacial dysmorphy. Moreover …
Inhibition of Bcl-2 synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia
J Ma, S Zhao, X Qiao, T Knight, H Edwards, L Polin… - Clinical Cancer …, 2019 - AACR
Purpose: To investigate the efficacy of the combination of the FLT3 inhibitors midostaurin or
gilteritinib with the Bcl-2 inhibitor venetoclax in FLT3-internal tandem duplication (ITD) acute …
gilteritinib with the Bcl-2 inhibitor venetoclax in FLT3-internal tandem duplication (ITD) acute …
Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN …
AL Blasius, E Giurisato, M Cella… - The Journal of …, 2006 - journals.aai.org
Type I IFN-producing cells (IPC) are sentinels of viral infections. Identification and functional
characterization of these cells have been difficult because of their small numbers in blood …
characterization of these cells have been difficult because of their small numbers in blood …
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
JH Klusmann, U Creutzig… - Blood, The Journal …, 2008 - ashpublications.org
Approximately 10% of the neonates with Down syndrome (DS) exhibit a unique transient
leukemia (TL). Though TL resolves spontaneously in most patients, early death and …
leukemia (TL). Though TL resolves spontaneously in most patients, early death and …
Binding of released Bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML …
Purpose: To investigate the molecular mechanism underlying intrinsic resistance to ABT-
199. Experimental Design: Western blots and real-time RT-PCR were used to determine …
199. Experimental Design: Western blots and real-time RT-PCR were used to determine …
Inhibition of Mcl-1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells
DA Luedtke, X Niu, Y Pan, J Zhao, S Liu… - Signal transduction and …, 2017 - nature.com
Acute myeloid leukemia (AML) is a serious disease. The 5-year survival rates remain
frustratingly low (65% for children and 26% for adults). Resistance to frontline chemotherapy …
frustratingly low (65% for children and 26% for adults). Resistance to frontline chemotherapy …
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome
S Malinge, M Bliss-Moreau… - The Journal of …, 2012 - Am Soc Clin Investig
Individuals with Down syndrome (DS; also known as trisomy 21) have a markedly increased
risk of leukemia in childhood but a decreased risk of solid tumors in adulthood. Acquired …
risk of leukemia in childhood but a decreased risk of solid tumors in adulthood. Acquired …
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling
JP Bourquin, A Subramanian… - Proceedings of the …, 2006 - National Acad Sciences
Individuals with Down syndrome (DS) are predisposed to develop acute megakaryoblastic
leukemia (AMKL), characterized by expression of truncated GATA1 transcription factor …
leukemia (AMKL), characterized by expression of truncated GATA1 transcription factor …
Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial
JW Taub, JN Berman, JK Hitzler… - Blood, The Journal …, 2017 - ashpublications.org
Patients with myeloid leukemia of Down syndrome (ML-DS) have favorable event-free
survival (EFS), but experience significant treatment-related morbidity and mortality. ML-DS …
survival (EFS), but experience significant treatment-related morbidity and mortality. ML-DS …